Naci, Huseyin

Number of items: 144.

Care Policy and Evaluation Centre

Knapp, Martin, Silva Ribeiro, Wagner, Naci, Huseyin, McDaid, David, Walbaum, Magdalena, Wong, Gloria, King, Derek, Anderson, Jodie, Bostock, Jennifer & Cyhlarova, Eva et al (2025). UKRI R&D missions accelerator programme NHS fit for the future: exploring the potential for greatest gains. London School of Economics and Political Science. Care Policy and Evaluation Centre.

Tinelli, Michela, Athanasiou, Antonios, Veroniki, Areti angeliki, Efthimiou, Orestis, Kalliala, Ilkka, Bowden, Sarah, Paraskevaidi, Maria, Lyons, Deirdre, Martin‐hirsch, Pierre & Bennett, Phillip et al (2024). Treatment methods for cervical intraepithelial neoplasia in England: a cost‐effectiveness analysis. BJOG: An International Journal of Obstetrics and Gynaecology, 131(10), 1411 - 1419. https://doi.org/10.1111/1471-0528.17829

Salcher-Konrad, Maximilian, Shi, Cheng, Patel, Disha, McDaid, David, Iveth Astudillo García, Claudia, Bobrow, Kirsten, Choy, Jacky C.P., Comas-Herrera, Adelina, Fry, Andra & Knapp, Martin et al (2023). Research evaluating the effectiveness of dementia interventions in low- and middle-income countries: a systematic mapping of 340 randomised controlled trials. International Journal of Geriatric Psychiatry, 38(7). https://doi.org/10.1002/gps.5965

Davis, Courtney, Wagner, Anita K., Salcher-Konrad, Maximilian, Scowcroft, Henry, Mintzes, Barbara, Pokorny, Adrian M J, Lew, Jianhui, Naci, Huseyin (2023). Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. BMJ, 380, e073711. https://doi.org/10.1136/bmj-2022-073711

Cherla, Avi, Mossialos, Elias, Salcher-Konrad, Maximilian, Kesselheim, Aaron S., Naci, Huseyin (2022). Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. Clinical Pharmacology and Therapeutics, 112(4), 846 - 852. https://doi.org/10.1002/cpt.2679

Salcher-Konrad, Maximilian, Naci, Huseyin, Davis, Courtney (2020). Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States. Milbank Quarterly, 98(4), 1219 - 1256. https://doi.org/10.1111/1468-0009.12476

Salcher-Konrad, Maximilian, Naci, Huseyin (2020). Unintended consequences of coverage laws targeting cancer drugs. Journal of Law, Medicine and Ethics, 48(3), 552-554. https://doi.org/10.1177/1073110520958880

Naci, Huseyin, Salcher-Konrad, Maximilian, Kesselheim, Aaron S., Dr.rer.nat, Beate Wiesler, Rochaix, Lise, Redberg, Rita, Salanti, Georgia, Jackson, Emily, Garner, Sarah & Stroup, Scott et al (2020). Generating comparative evidence on new drugs and devices before approval. The Lancet, 395(10228), 986 - 997. https://doi.org/10.1016/S0140-6736(19)33178-2

Salcher-Konrad, Maximilian, Naci, Huseyin, McDaid, David, Alladi, Suvarna, Oliveira, Déborah, Fry, Andra, Hussein, Shereen, Knapp, Martin, Comas-Herrera, Adelina & Musyimi, Christine et al (2019). Effectiveness of interventions for dementia in low- and middle-income countries: protocol for a systematic review, pairwise and network meta-analysis. BMJ Open, 9(6). https://doi.org/10.1136/bmjopen-2018-027851

Naci, Huseyin, Salcher-Konrad, Maximilian, Mcguire, Alistair, Berger, Felix, Kuehne, Titus, Goubergrits, Leonid, Muthurangu, Vivek, Wilson, Ben, Kelm, Marcus (2019). Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease. npj Digital Medicine, 2(1). https://doi.org/10.1038/s41746-019-0085-1

Luyten, Jeroen, Naci, Huseyin, Knapp, Martin (2016). Economic evaluation of mental health interventions: an introduction to cost-utility analysis. Evidence-Based Mental Health, 19, 49-53. https://doi.org/10.1136/eb-2016-102354

European Observatory on Health Systems

de Sá, Thiago Hérick, Sudsataya, Daniele, Fry, Andra, Salehi, Nazak, Katiki, Aishwarya, Mcleod, Megan, Rathmell, Greg, Cylus, Jon, Lafortune, Louise & Buffel, Tine et al (2024). The impact of transport, housing, and urban development interventions on older adults' mobility: a systematic review of experimental and quasi-experimental studies. Journal of Transport and Health, 38, https://doi.org/10.1016/j.jth.2024.101859

Health Policy

Papanicolas, Irene, Wouters, Olivier J., Sawaya, Tania, Han, Jihye, Wei, Jinru, Naci, Huseyin (2026). Review times for new drugs and submission delays among the FDA and 4 international regulators, 2014–22. Health Affairs, 45(2), 184-192. https://doi.org/10.1377/hlthaff.2025.00595

McGonigle, Rylee, Naci, Huseyin, Siebert, Maximilian, Ouvina, Michelle, Gutierrez-Sacristan, Alba, Wagner, Anita K., Bourgeois, Florence T. (2025). Pediatric studies and labeling additions required by the U.S. FDA for novel drugs approved from 2011 to 2023: a retrospective cohort study. PLoS Medicine, 22(12). https://doi.org/10.1371/journal.pmed.1004651

Naci, Huseyin, Shahzad, Mahnum, Murphy, Peter, Zhang, Yichen, Costa, Rebecca, Ross, Joseph S., Wagner, Anita K. (2025). Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation. BMJ Medicine, 4(1). https://doi.org/10.1136/bmjmed-2025-001934

Knapp, Martin, Silva Ribeiro, Wagner, Naci, Huseyin, McDaid, David, Walbaum, Magdalena, Wong, Gloria, King, Derek, Anderson, Jodie, Bostock, Jennifer & Cyhlarova, Eva et al (2025). UKRI R&D missions accelerator programme NHS fit for the future: exploring the potential for greatest gains. London School of Economics and Political Science. Care Policy and Evaluation Centre.

Cherla, Avi, Wagner, Anita K., Wouters, Olivier J., Woloshin, Steven, Davis, Courtney, Mossialos, Elias, Naci, Huseyin (2025). Reporting of clinical trial uncertainties with new cancer drugs in journal publications and clinical guidelines. JAMA, 334(16), 1480 - 1482. https://doi.org/10.1001/jama.2025.13917

Zhang, Yichen, Li, Huangqianyu, Chen, Jinyu, Naci, Huseyin, Wagner, Anita K, Shi, Luwen, Guan, Xiaodong (2025). Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study. BMJ Evidence-Based Medicine, https://doi.org/10.1136/bmjebm-2025-113722

Zhang, Yichen, Chen, Dingyi, Fu, Mengyuan, Shi, Luwen, Naci, Huseyin, Wagner, Anita K., Ross, Joseph S., Guan, Xiaodong (2025). Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. The Lancet Oncology, 26(9), 1252 - 1260. https://doi.org/10.1016/S1470-2045(25)00329-8

Gainsbury, Sally, Naci, Huseyin (2025). Improving productivity in the NHS. BMJ, 390, https://doi.org/10.1136/bmj.r1722

Cherla, Avi, Woloshin, Steven, Wagner, Anita K., Wouters, Olivier J., Davis, Courtney, Mossialos, Elias, Naci, Huseyin (2025). New cancer drug approvals: less than half of important clinical trial uncertainties reported by the FDA to clinicians, 2019–22. Health Affairs, 44(7), 830 - 838. https://doi.org/10.1377/hlthaff.2024.01134

Naci, Huseyin, Murphy, Peter, Woods, Beth, Lomas, James, Wei, Jinru, Papanicolas, Irene (2025). Population health impact of NICE-recommended new drugs – authors' reply. The Lancet, 405(10497), 2277 - 2278. https://doi.org/10.1016/S0140-6736(25)01078-5

Cherla, Avi, Naci, Huseyin, Woloshin, Steven, Wagner, Anita Katharina, Ong, Mei-Sing (2025). Communication of uncertainties about recent cancer drugs in large language models. Journal of Clinical Oncology, 43(16_suppl), 11026 - 11026. https://doi.org/10.1200/jco.2025.43.16_suppl.11026

Zhang, Yichen, Chen, Dingyi, Fu, Mengyuan, Shi, Luwen, Naci, Huseyin, Wagner, Anita Katharina, Ross, Joseph S., Guan, Xiaodong (2025). Strength of evidence supporting cancer drug approvals in China, 2017-2021. Journal of Clinical Oncology, 43(16_suppl). https://doi.org/10.1200/jco.2025.43.16_suppl.tps11188

Pollicino, Daniele, Zamzow, Heidi, Shreedhar, Ganga, Galizzi, Matteo M., Naci, Huseyin, Freitag, Patricia (2025). Can social norms promote sustainable food consumption? A systematic review. Social Influence, 20(1). https://doi.org/10.1080/15534510.2025.2497341

Naci, Huseyin, Murphy, Peter, Woods, Beth, Lomas, James, Wei, Jinru, Papanicolas, Irene (2025). Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis. The Lancet, 405(10472), 50 - 60. https://doi.org/10.1016/S0140-6736(24)02352-3

Forrest, Robin, Lagarde, Mylene, Aggarwal, Ajay, Naci, Huseyin (2024). Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. The Lancet Oncology, 25(12), 1635 - 1643. https://doi.org/10.1016/S1470-2045(24)00596-5

Shahzad, Mahnum, Naci, Huseyin, Esselen, Katharine M., Dottino, Joseph A., Wagner, Anita K. (2024). Regulatory histories of recently withdrawn ovarian cancer treatment indications of 3 PARP inhibitors in the US and Europe: lessons for the accelerated approval pathway. Journal of Pharmaceutical Policy and Practice, 17(1). https://doi.org/10.1080/20523211.2024.2351003

Naci, Huseyin, Woods, Beth, Lomas, James, Wei, Jinru (13 December 2024) Why pharmaceutical pricing needs reform. British Politics and Policy at LSE.

Lythgoe, Mark P., Emhardt, Alica Joana, Naci, Huseyin, Krell, Jonathan, Sullivan, Richard, Aggarwal, Ajay (2024). Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysis. The Lancet Regional Health - Europe, 46, https://doi.org/10.1016/j.lanepe.2024.101062

Soumerai, Stephen B., Koppel, Ross, Naci, Huseyin, Madden, Jeanne M., Fry, Andra, Halbisen, Alyssa, Angeles, Jesenia, Koppel, Jonah, Rubin, Rachelle, Lu, Christine Y. (2024). Intended and unintended outcomes after FDA pediatric antidepressant warnings: a systematic review. Health affairs (Project Hope), 43(10), 1360 - 1369. https://doi.org/10.1377/hlthaff.2023.00263

Davis, Courtney, Wagner, Anita K., Mintzes, Barbara, Scowcroft, Henry, Woloshin, Steven, Naci, Huseyin (2024). Patients deserve better information on new drugs. BMJ (Clinical research ed.), 387, https://doi.org/10.1136/bmj-2024-081720

Salcher-Konrad, Maximilian, Nguyen, Mary, Savović, Jelena, Higgins, Julian P. T., Naci, Huseyin (2024). Treatment effects in randomized and nonrandomized studies of pharmacological interventions: a meta-analysis. JAMA network open, 7(9). https://doi.org/10.1001/jamanetworkopen.2024.36230

Tinelli, Michela, Athanasiou, Antonios, Veroniki, Areti angeliki, Efthimiou, Orestis, Kalliala, Ilkka, Bowden, Sarah, Paraskevaidi, Maria, Lyons, Deirdre, Martin‐hirsch, Pierre & Bennett, Phillip et al (2024). Treatment methods for cervical intraepithelial neoplasia in England: a cost‐effectiveness analysis. BJOG: An International Journal of Obstetrics and Gynaecology, 131(10), 1411 - 1419. https://doi.org/10.1111/1471-0528.17829

de Sá, Thiago Hérick, Sudsataya, Daniele, Fry, Andra, Salehi, Nazak, Katiki, Aishwarya, Mcleod, Megan, Rathmell, Greg, Cylus, Jon, Lafortune, Louise & Buffel, Tine et al (2024). The impact of transport, housing, and urban development interventions on older adults' mobility: a systematic review of experimental and quasi-experimental studies. Journal of Transport and Health, 38, https://doi.org/10.1016/j.jth.2024.101859

Wouters, Olivier J., Naci, Huseyin, Papanicolas, Irene (2024). Health Technology Assessment in the US—a word of caution—reply. JAMA Internal Medicine, 184(7), 851 - 851. https://doi.org/10.1001/jamainternmed.2024.1461

Naci, Huseyin, Zhang, Yichen, Woloshin, Steven, Guan, Xiaodong, Xu, Ziyue, Wagner, Anita K. (2024). Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. The Lancet Oncology, 25(6), 760 - 769. https://doi.org/10.1016/S1470-2045(24)00152-9

Wei, Yuxuan, Zhang, Yichen, Xu, Ziyue, Wang, Guoan, Zhou, Yue, Li, Huangqianyu, Shi, Luwen, Naci, Huseyin, Wagner, Anita K., Guan, Xiaodong (2024). Cancer drug indication approvals in China and the United States: a comparison of approval times and clinical benefit, 2001–2020. The Lancet Regional Health - Western Pacific, 45, https://doi.org/10.1016/j.lanwpc.2024.101055

Swift, Bethan, Taneri, Bahar, Becker, Christian M., Basarir, Hasan, Naci, Huseyin, Missmer, Stacey A., Zondervan, Krina T., Rahmioglu, Nilufer (2024). Prevalence, diagnostic delay and economic burden of endometriosis and its impact on quality of life: results from an Eastern Mediterranean population. European Journal of Public Health, 34(2), 244 - 252. https://doi.org/10.1093/eurpub/ckad216

Wouters, Olivier J., Naci, Huseyin, Papanicolas, Irene (2024). Availability and coverage of new drugs in 6 high-income countries with health technology assessment bodies. Journal of American Medical Association: Internal Medicine, 184(3), 328 - 330. https://doi.org/10.1001/jamainternmed.2023.7726

Zhou, Yue, Naci, Huseyin, Chen, Dingyi, Bai, Lin, Shi, Luwen, Guan, Xiaodong, Wagner, Anita Katharina (2023). Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021. BMJ Global Health, 8(9). https://doi.org/10.1136/bmjgh-2023-012899

Salcher-Konrad, Maximilian, Shi, Cheng, Patel, Disha, McDaid, David, Iveth Astudillo García, Claudia, Bobrow, Kirsten, Choy, Jacky C.P., Comas-Herrera, Adelina, Fry, Andra & Knapp, Martin et al (2023). Research evaluating the effectiveness of dementia interventions in low- and middle-income countries: a systematic mapping of 340 randomised controlled trials. International Journal of Geriatric Psychiatry, 38(7). https://doi.org/10.1002/gps.5965

Ivama-Brummell, Adriana M., Marciniuk, Fernanda L, Wagner, Anita K., Osorio-de-Castro, Claudia G. S., Vogler, Sabine, Mossialos, Elias, Tavares-de-Andrade, Carla L., Naci, Huseyin (2023). Marketing authorisation and pricing of FDA-approved cancer drugs in Brazil: a retrospective analysis. The Lancet Regional Health - Americas, 22, https://doi.org/10.1016/j.lana.2023.100506

Parvanova, Iva, Gentilini, Arianna, Cushing, Jonathan, Naci, Huseyin (2023). Safeguarding NICE from patient groups' conflicts of interest. BMJ, 381, https://doi.org/10.1136/bmj.p1243

Forrest, Robin, Naci, Huseyin (2023). Prioritising patients in negotiations over drug pricing. BMJ (Clinical research ed.), 381, https://doi.org/10.1136/bmj.p829

Cherla, Avi, Davis, Courtney, Mossialos, Elias, Naci, Huseyin (2023). Faster UK drug approvals by relying on other countries. BMJ (Clinical research ed.), 381, p. 739. https://doi.org/10.1136/bmj.p739

Davis, Courtney, Wagner, Anita K., Salcher-Konrad, Maximilian, Scowcroft, Henry, Mintzes, Barbara, Pokorny, Adrian M J, Lew, Jianhui, Naci, Huseyin (2023). Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe. BMJ, 380, e073711. https://doi.org/10.1136/bmj-2022-073711

Shahzad, Mahnum, Naci, Huseyin, Wagner, Anita K. (2023). Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway. JAMA, 329(9), 760 - 761. https://doi.org/10.1001/jama.2023.0625

Naci, Huseyin, Forrest, Robin, Zhai, Mike, Stofesky, Amanda R., Kesselheim, Aaron S. (2023). Characteristics of prior authorization policies for new drugs in Medicare Part D. JAMA Health Forum, 4(2). https://doi.org/10.1001/jamahealthforum.2022.5610

Vokinger, Kerstin N., Naci, Huseyin (2022). Negotiating drug prices in the US - lessons from Europe. JAMA Health Forum, 3(12). https://doi.org/10.1001/jamahealthforum.2022.4801

Ostinelli, Edoardo Giuseppe, Efthimiou, Orestis, Naci, Huseyin, Furukawa, Toshi A., Leucht, Stefan, Salanti, Georgia, Wainwright, Laurence, Zangani, Caroline, De Crescenzo, Franco & Smith, Katharine et al (2022). Vitruvian plot: a visualisation tool for multiple outcomes in network meta-analysis. Evidence-Based Mental Health, 25(e1), e65 - e70. https://doi.org/10.1136/ebmental-2022-300457

Carl, David L., Laube, Yannic, Serra-Burriel, Miquel, Naci, Huseyin, Ludwig, Wolf Dieter, Vokinger, Kerstin N. (2022). Comparison of uptake and prices of biosimilars in the US, Germany, and Switzerland. JAMA network open, 5(12). https://doi.org/10.1001/jamanetworkopen.2022.44670

Cherla, Avi, Mossialos, Elias, Salcher-Konrad, Maximilian, Kesselheim, Aaron S., Naci, Huseyin (2022). Post-marketing requirements for cancer drugs approved by the European Medicines Agency, 2004-2014. Clinical Pharmacology and Therapeutics, 112(4), 846 - 852. https://doi.org/10.1002/cpt.2679

Blankart, Katharina, Naci, Huseyin, Chandra, Amitabh (2022). Availability of new medicines in the US and Germany from 2004 to 2018. JAMA network open, 5(8). https://doi.org/10.1001/jamanetworkopen.2022.29231

Athanasiou, Antonios, Veroniki, Areti Angeliki, Efthimiou, Orestis, Kalliala, Ilkka, Naci, Huseyin, Bowden, Sarah, Paraskevaidi, Maria, Arbyn, Marc, Lyons, Deirdre & Martin-Hirsch, Pierre et al (2022). Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis. The Lancet Oncology, 23(8), 1097 - 1108. https://doi.org/10.1016/S1470-2045(22)00334-5

Costa, Suzete, Romão, Mariana, Mendes, Maria, Horta, Maria Rute, Rodrigues, António Teixeira, Carneiro, António Vaz, Martins, Ana Paula, Mallarini, Erika, Naci, Huseyin, Babar, Zaheer Ud Din (2022). Pharmacy interventions on COVID-19 in Europe: mapping current practices and a scoping review. Research in Social and Administrative Pharmacy, 18(8), 3338 - 3349. https://doi.org/10.1016/j.sapharm.2021.12.003

Swift, B., Naci, H., Taneri, B., Becker, C. M., Zondervan, K. T., Rahmioglu, N. (2022). The Cyprus Women’s Health Research (COHERE) initiative: normative data from the SF-36v2 questionnaire for reproductive aged women from the Eastern Mediterranean. Quality of Life Research, 31(7), 2011 - 2022. https://doi.org/10.1007/s11136-022-03100-7

Naci, Huseyin, Kyriopoulos, Ilias-Ioannis, Feldman, William B., Hwang, Thomas J., Kesselheim, Aaron S., Chandra, Amitabh (2022). Coverage of new drugs in Medicare Part D. Milbank Quarterly, 100(2), 562 - 588. https://doi.org/10.1111/1468-0009.12565

Kapelios, Chris J., Naci, Huseyin, Vardas, Panos E., Mossialos, Elias (2022). Study design, result posting, and publication of late-stage cardiovascular trials. European Heart Journal - Quality of Care and Clinical Outcomes, 8(3), 277 - 288. https://doi.org/10.1093/ehjqcco/qcaa080

Vokinger, Kerstin N., Hwang, Thomas J., Carl, David L., Laube, Yannic, Ludwig, Wolf Dieter, Naci, Huseyin, Kesselheim, Aaron S. (2022). Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis. The Lancet Oncology, 23(4), 514 - 520. https://doi.org/10.1016/S1470-2045(22)00073-0

Bartholomew, Theodore, Naci, Huseyin, Robertson, Emma, Schmidt, Harald (2022). Use of adherence monitoring in drug contracts tied to outcomes: put patients first. BMJ (Clinical research ed.), 376, https://doi.org/10.1136/bmj-2020-062188

Fu, Mengyuan, Naci, Huseyin, Booth, Christopher M., Gyawali, Bishal, Cosgrove, Austin, Toh, Sengwee, Xu, Ziyue, Guan, Xiaodong, Ross-Degnan, Dennis, Wagner, Anita K. (2021). Real-world use of and spending on new oral targeted cancer Drugs in the US, 2011-2018. JAMA Internal Medicine, 181(12), 1596 - 1604. https://doi.org/10.1001/jamainternmed.2021.5983

Naci, Huseyin, Guan, Xiaodong, Woloshin, Steven, Xu, Ziyue, Wagner, Anita K. (2021). Communication of survival data in US Food and Drug Administration-approved labeling of cancer drugs. JAMA Internal Medicine, 181(11), 1521 - 1522. https://doi.org/10.1001/jamainternmed.2021.3505

Dawoud, Dalia, Naci, Huseyin, Ciani, Oriana, Bujkiewicz, Sylwia (2021). Raising the bar for using surrogate endpoints in drug regulation and health technology assessment. The BMJ, 374, https://doi.org/10.1136/bmj.n2191

Cherla, Avi, Naci, Huseyin, Mossialos, Elias (2021). The coverage in England of US-approved cancer drugs reply: in reply. JAMA Internal Medicine, 181(9), 1263 - 1264. https://doi.org/10.1001/jamainternmed.2021.3339

Beirne, Anne Marie, Mitchelmore, Oliver, Palma, Susana, Andiapen, Mervyn, Rathod, Krishnaraj S., Hammond, Victoria, Bellin, Anna, Cooper, Jackie, Wright, Paul & Antoniou, Sotiris et al (2021). NITRATE-CIN Study: Protocol of a Randomized (1:1) Single-Center, UK, Double-Blind Placebo-Controlled Trial Testing the Effect of Inorganic Nitrate on Contrast-Induced Nephropathy in Patients Undergoing Coronary Angiography for Acute Coronary Syndromes. Journal of Cardiovascular Pharmacology and Therapeutics, 26(4), 303-309. https://doi.org/10.1177/1074248421000520

Cherla, Avi, Naci, Huseyin, Kesselheim, Aaron S., Gyawali, Bishal, Mossialos, Elias (2021). Assessment of coverage in England of cancer drugs qualifying for US food and drug administration accelerated approval. JAMA Internal Medicine, 181(4), 490 - 498. https://doi.org/10.1001/jamainternmed.2020.8441

Petersen, Steffen E., Friebel, Rocco, Ferrari, Victor, Han, Yuchi, Aung, Nay, Kenawy, Asmaa, Albert, Timothy S.E., Naci, Huseyin (2021). Recent trends and potential drivers of non-invasive cardiovascular imaging use in the United States of America and England. Frontiers in Cardiovascular Medicine, 7, https://doi.org/10.3389/fcvm.2020.617771

Salcher-Konrad, Maximilian, Naci, Huseyin, Davis, Courtney (2020). Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States. Milbank Quarterly, 98(4), 1219 - 1256. https://doi.org/10.1111/1468-0009.12476

Angelis, Aris, Naci, Huseyin, Hackshaw, Allan (2020). Recalibrating health technology assessment methods for cell and gene therapies. PharmacoEconomics, 38(12), 1297-1308. https://doi.org/10.1007/s40273-020-00956-w

Naci, Huseyin, Kesselheim, Aaron S., Rttingen, John Arne, Salanti, Georgia, Vandvik, Per O., Cipriani, Andrea (2020). Producing and using timely comparative evidence on drugs: lessons from clinical trials for covid-19. The BMJ, 371, https://doi.org/10.1136/bmj.m3869

Salcher-Konrad, Maximilian, Naci, Huseyin (2020). Unintended consequences of coverage laws targeting cancer drugs. Journal of Law, Medicine and Ethics, 48(3), 552-554. https://doi.org/10.1177/1073110520958880

Vreman, Rick A., Naci, Huseyin, Goettsch, Wim G., Mantel-Teeuwisse, Aukje K., Schneeweiss, Sebastian G., Leufkens, Hubert G.M., Kesselheim, Aaron S. (2020). Decision making under uncertainty: comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Clinical Pharmacology and Therapeutics, 108(2), 350-357. https://doi.org/10.1002/cpt.1835

Naci, Huseyin, Kesselheim, Aaron S. (2020). Specialty drugs: a distinctly American phenomenon. New England Journal of Medicine, 382(23), 2179 - 2181. https://doi.org/10.1056/NEJMp1909513

Singh, Ilina, Naci, Huseyin, Miller, Jennifer, Caplan, Arthur, Cipriani, Andrea (2020). Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships. The Lancet, 395(10228), 926 - 928. https://doi.org/10.1016/S0140-6736(20)30413-X

Cipriani, Andrea, Ioannidis, John P.A., Rothwell, Peter M., Glasziou, Paul, Li, Tianjing, Hernandez, Adrian F., Tomlinson, Anneka, Simes, John, Naci, Huseyin (2020). Generating comparative evidence on new drugs and devices after approval. The Lancet, 395(10228), 998-1010. https://doi.org/10.1016/S0140-6736(19)33177-0

Naci, Huseyin, Salcher-Konrad, Maximilian, Kesselheim, Aaron S., Dr.rer.nat, Beate Wiesler, Rochaix, Lise, Redberg, Rita, Salanti, Georgia, Jackson, Emily, Garner, Sarah & Stroup, Scott et al (2020). Generating comparative evidence on new drugs and devices before approval. The Lancet, 395(10228), 986 - 997. https://doi.org/10.1016/S0140-6736(19)33178-2

Pinto, Ashlyn, Naci, Huseyin, Neez, Emilie, Mossialos, Elias (2020). Association between the use of surrogate measures in pivotal trials and health technology assessment decisions: a retrospective analysis of NICE and CADTH reviews of cancer drugs. Value in Health, 23(3), 319-327. https://doi.org/10.1016/j.jval.2019.10.010

Aung, Nay, Doimo, Sara, Ricci, Fabrizio, Sanghvi, Mihir M., Pedrosa, Cesar, Woodbridge, Simon P., Al-Balah, Amer, Zemrak, Filip, Khanji, Mohammed Y. & Munroe, Patricia B. et al (2020). Prognostic significance of left ventricular noncompaction: systematic review and meta-analysis of observational studies. Circulation: Cardiovascular Imaging, 13(1). https://doi.org/10.1161/CIRCIMAGING.119.009712

Athanasiou, Antonios, Veroniki, Areti Angeliki, Efthimiou, Orestis, Kalliala, Ilkka, Naci, Huseyin, Bowden, Sarah, Paraskevaidi, Maria, Martin-Hirsch, Pierre, Bennett, Philip & Paraskevaidis, Evangelos et al (2019). Comparative fertility and pregnancy outcomes after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE group. BMJ Open, 9(10). https://doi.org/10.1136/bmjopen-2018-028009

Neez, Emilie Marie Celine Anne, Hwang, Thomas, Sahoo, Samali Anova, Naci, Huseyin (2019). European Medicines Agency’s Priority Medicines scheme at 2 years: an evaluation of clinical studies supporting eligible drugs. Clinical Pharmacology and Therapeutics, 107(3), 541-552. https://doi.org/10.1002/cpt.1669

Naci, Huseyin, Davis, Courtney, Savović, Jelena, Higgins, Julian P. T., Sterne, Jonathan, Gyawali, Bishal, Romo Sandoval, Xochitl Citlalli, Handley, Nicola, Booth, Christopher M (2019). Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross-sectional analysis. BMJ, 366(8214). https://doi.org/10.1136/bmj.l5221

Athanasiou, Antonios, Veroniki, Areti Angeliki, Efthimiou, Orestis, Kalliala, Ilkka, Naci, Huseyin, Bowden, Sarah, Paraskevaidi, Maria, Martin-Hirsch, Pierre, Bennett, Philip & Paraskevaidis, Evangelos et al (2019). Comparative efficacy and complication rates after local treatment for cervical intraepithelial neoplasia and stage 1a1 cervical cancer: protocol for a systematic review and network meta-analysis from the CIRCLE Group. BMJ Open, 9(8). https://doi.org/10.1136/bmjopen-2018-028008

Salcher-Konrad, Maximilian, Naci, Huseyin, McDaid, David, Alladi, Suvarna, Oliveira, Déborah, Fry, Andra, Hussein, Shereen, Knapp, Martin, Comas-Herrera, Adelina & Musyimi, Christine et al (2019). Effectiveness of interventions for dementia in low- and middle-income countries: protocol for a systematic review, pairwise and network meta-analysis. BMJ Open, 9(6). https://doi.org/10.1136/bmjopen-2018-027851

Hocaoglu, M. B., Gurkas, S., Karaderi, T., Taneri, B., Erguler, K., Barin, B., Bilgin, E. M., Eralp, G., Allison, M. & Findikli, N. et al (2019). Cyprus women's health research (COHERE) initiative: determining the relative burden of women's health conditions and related co-morbidities in an Eastern Mediterranean population. BMC Women's Health, 19(1). https://doi.org/10.1186/s12905-019-0750-1

Hopkin, Gareth, Au, Anson, Collier, Verena Jane, Yudkin, John S, Basu, Sanjay, Naci, Huseyin (2019). Combining multiple treatment comparisons with personalized patient preferences: a randomized trial of an interactive platform for statin treatment selection. Medical Decision Making, 39(3), 264-277. https://doi.org/10.1177/0272989X19835239

Choi, Sung Eun, Berkowitz, Seth A., Yudkin, John S., Naci, Huseyin, Basu, Sanjay (2019). Personalizing second-line Type 2 diabetes treatment selection: combining network meta-analysis, individualized risk, and patient preferences for unified decision support. Medical Decision Making, 39(3), 239-252. https://doi.org/10.1177/0272989X19829735

Naci, Huseyin, Salcher-Konrad, Maximilian, Mcguire, Alistair, Berger, Felix, Kuehne, Titus, Goubergrits, Leonid, Muthurangu, Vivek, Wilson, Ben, Kelm, Marcus (2019). Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease. npj Digital Medicine, 2(1). https://doi.org/10.1038/s41746-019-0085-1

Naci, Huseyin, Dixon, Jennifer (2019). New agreement on branded drugs for the NHS. BMJ (Online), 364, p. 1266. https://doi.org/10.1136/bmj.l266

Naci, Huseyin, Salcher-Konrad, Maximilian, Dias, Sofia, Blum, Manuel R., Sahoo, Samali Anova, Nunan, David, Ioannidis, John P. A. (2018). How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 RCTs assessing exercise and medication effects on systolic blood pressure. British Journal of Sports Medicine, https://doi.org/10.1136/bjsports-2018-099921

Crispi, Francisca, Naci, Huseyin, Barkauskaite, Eva, Osipenko, Leeza, Mossialos, Elias (2018). Assessment of devices, diagnostics and digital technologies: a review of NICE medical technologies guidance. Applied Health Economics and Health Policy, https://doi.org/10.1007/s40258-018-0438-y

Anderson, Michael, Naci, Huseyin, Morrison, Deborah, Osipenko, Leeza, Mossialos, Elias (2018). A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. Journal of Clinical Epidemiology, https://doi.org/10.1016/j.jclinepi.2018.09.003

Wallach, Joshua D., Ross, Joseph S., Naci, Huseyin (2018). The US Food and Drug Administration’s expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements. Clinical Trials, https://doi.org/10.1177/1740774518770648

Naci, Huseyin, Vardas, Panos, Vahanian, Alec, Kirchhof, Paulus, Bardinet, Isabel, Mossialos, Elias (2017). Training the next generation of cardiovascular leaders in health policy and economics. European Heart Journal, 38(45), 3332-3335. https://doi.org/10.1093/eurheartj/ehx673

Naci, Huseyin, Mossialos, Elias (2017). Accelerated access to new drugs and technologies. BMJ, 359, 1-2. https://doi.org/10.1136/bmj.j5387

Davis, Courtney, Naci, Huseyin, Gurpinar, Evrim, Poplavska, Elita, Pinto, Ashlyn, Aggarwal, Ajay (2017). Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ, 359(359). https://doi.org/10.1136/bmj.j4530

Naci, Huseyin, Smalley, Katelyn R., Kesselheim, Aaron S. (2017). Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US food and drug administration. JAMA, 318(7), 626-636. https://doi.org/10.1001/jama.2017.9415

LSE

Soumerai, Stephen B., Koppel, Ross, Naci, Huseyin, Madden, Jeanne M., Fry, Andra, Halbisen, Alyssa, Angeles, Jesenia, Koppel, Jonah, Rubin, Rachelle, Lu, Christine Y. (2024). Intended and unintended outcomes after FDA pediatric antidepressant warnings: a systematic review. Health affairs (Project Hope), 43(10), 1360 - 1369. https://doi.org/10.1377/hlthaff.2023.00263

de Sá, Thiago Hérick, Sudsataya, Daniele, Fry, Andra, Salehi, Nazak, Katiki, Aishwarya, Mcleod, Megan, Rathmell, Greg, Cylus, Jon, Lafortune, Louise & Buffel, Tine et al (2024). The impact of transport, housing, and urban development interventions on older adults' mobility: a systematic review of experimental and quasi-experimental studies. Journal of Transport and Health, 38, https://doi.org/10.1016/j.jth.2024.101859

Salcher-Konrad, Maximilian, Nguyen, Mary, Naci, Huseyin (2024). Dataset: effect estimates obtained from randomised and non-randomised studies. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.4958221

Salcher-Konrad, Maximilian, Shi, Cheng, Patel, Disha, McDaid, David, Iveth Astudillo García, Claudia, Bobrow, Kirsten, Choy, Jacky C.P., Comas-Herrera, Adelina, Fry, Andra & Knapp, Martin et al (2023). Research evaluating the effectiveness of dementia interventions in low- and middle-income countries: a systematic mapping of 340 randomised controlled trials. International Journal of Geriatric Psychiatry, 38(7). https://doi.org/10.1002/gps.5965

Olczak, Kaya, Salcher, Maximillian, Naci, Huseyin (2016). What works best in congenital heart disease? Comparing two interventions for treatment of Aortic Coarctation.

Salcher, Maximilian, Naci, Huseyin, Law, Tyler J., Kuehne, Titus, Schubert, Stephan, Kelm, Marcus (2016). Balloon dilatation and stenting for aortic coarctation: a systematic review and meta-analysis. Circulation: Cardiovascular Interventions, https://doi.org/10.1161/CIRCINTERVENTIONS.115.003153

Naci, Huseyin, Brugts, Jasper Jan, Fleurence, Rachael, Ades, Anthony E. (2013). Comparative effects of statins on major cerebrovascular events: a multiple-treatments meta-analysis of placebo-controlled and active-comparator trials. QJM - Monthly Journal of the Association of Physicians, 106(4), 299-306. https://doi.org/10.1093/qjmed/hct041

Naci, H., Ioannidis, J. P. A. (2013). Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. The BMJ, 347(oct01), 1-14. https://doi.org/10.1136/bmj.f5577

LSE Health

Zhang, Yichen, Li, Huangqianyu, Chen, Jinyu, Naci, Huseyin, Wagner, Anita K, Shi, Luwen, Guan, Xiaodong (2025). Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study. BMJ Evidence-Based Medicine, https://doi.org/10.1136/bmjebm-2025-113722

Zhang, Yichen, Chen, Dingyi, Fu, Mengyuan, Shi, Luwen, Naci, Huseyin, Wagner, Anita K., Ross, Joseph S., Guan, Xiaodong (2025). Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis. The Lancet Oncology, 26(9), 1252 - 1260. https://doi.org/10.1016/S1470-2045(25)00329-8

Forrest, Robin, Lagarde, Mylene, Aggarwal, Ajay, Naci, Huseyin (2024). Preferences for speed of access versus certainty of the survival benefit of new cancer drugs: a discrete choice experiment. The Lancet Oncology, 25(12), 1635 - 1643. https://doi.org/10.1016/S1470-2045(24)00596-5

Salcher-Konrad, Maximilian, Shi, Cheng, Patel, Disha, McDaid, David, Iveth Astudillo García, Claudia, Bobrow, Kirsten, Choy, Jacky C.P., Comas-Herrera, Adelina, Fry, Andra & Knapp, Martin et al (2023). Research evaluating the effectiveness of dementia interventions in low- and middle-income countries: a systematic mapping of 340 randomised controlled trials. International Journal of Geriatric Psychiatry, 38(7). https://doi.org/10.1002/gps.5965

Parvanova, Iva, Gentilini, Arianna, Cushing, Jonathan, Naci, Huseyin (2023). Safeguarding NICE from patient groups' conflicts of interest. BMJ, 381, https://doi.org/10.1136/bmj.p1243

Zhang, Yichen, Naci, Huseyin, Wagner, Anita K., Xu, Ziyue, Yang, Yu, Zhu, Jun, Ji, Jiafu, Shi, Luwen, Guan, Xiaodong (2022). Overall survival benefits of cancer drugs approved in China from 2005 to 2020. JAMA network open, 5(8). https://doi.org/10.1001/jamanetworkopen.2022.25973

Salcher-Konrad, Maximilian, Naci, Huseyin, Davis, Courtney (2020). Approval of cancer drugs with uncertain therapeutic value: a comparison of regulatory decisions in Europe and the United States. Milbank Quarterly, 98(4), 1219 - 1256. https://doi.org/10.1111/1468-0009.12476

Angelis, Aris, Naci, Huseyin, Hackshaw, Allan (2020). Recalibrating health technology assessment methods for cell and gene therapies. PharmacoEconomics, 38(12), 1297-1308. https://doi.org/10.1007/s40273-020-00956-w

Singh, Ilina, Naci, Huseyin, Miller, Jennifer, Caplan, Arthur, Cipriani, Andrea (2020). Ethical implications of poor comparative effectiveness evidence: obligations in industry-research partnerships. The Lancet, 395(10228), 926 - 928. https://doi.org/10.1016/S0140-6736(20)30413-X

Naci, Huseyin, Salcher-Konrad, Maximilian, Kesselheim, Aaron S., Dr.rer.nat, Beate Wiesler, Rochaix, Lise, Redberg, Rita, Salanti, Georgia, Jackson, Emily, Garner, Sarah & Stroup, Scott et al (2020). Generating comparative evidence on new drugs and devices before approval. The Lancet, 395(10228), 986 - 997. https://doi.org/10.1016/S0140-6736(19)33178-2

Aung, Nay, Doimo, Sara, Ricci, Fabrizio, Sanghvi, Mihir M., Pedrosa, Cesar, Woodbridge, Simon P., Al-Balah, Amer, Zemrak, Filip, Khanji, Mohammed Y. & Munroe, Patricia B. et al (2020). Prognostic significance of left ventricular noncompaction: systematic review and meta-analysis of observational studies. Circulation: Cardiovascular Imaging, 13(1). https://doi.org/10.1161/CIRCIMAGING.119.009712

Neez, Emilie Marie Celine Anne, Hwang, Thomas, Sahoo, Samali Anova, Naci, Huseyin (2019). European Medicines Agency’s Priority Medicines scheme at 2 years: an evaluation of clinical studies supporting eligible drugs. Clinical Pharmacology and Therapeutics, 107(3), 541-552. https://doi.org/10.1002/cpt.1669

Salcher-Konrad, Maximilian, Naci, Huseyin, McDaid, David, Alladi, Suvarna, Oliveira, Déborah, Fry, Andra, Hussein, Shereen, Knapp, Martin, Comas-Herrera, Adelina & Musyimi, Christine et al (2019). Effectiveness of interventions for dementia in low- and middle-income countries: protocol for a systematic review, pairwise and network meta-analysis. BMJ Open, 9(6). https://doi.org/10.1136/bmjopen-2018-027851

Naci, Huseyin, Salcher-Konrad, Maximilian, Mcguire, Alistair, Berger, Felix, Kuehne, Titus, Goubergrits, Leonid, Muthurangu, Vivek, Wilson, Ben, Kelm, Marcus (2019). Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease. npj Digital Medicine, 2(1). https://doi.org/10.1038/s41746-019-0085-1

Anderson, Michael, Naci, Huseyin, Morrison, Deborah, Osipenko, Leeza, Mossialos, Elias (2018). A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. Journal of Clinical Epidemiology, https://doi.org/10.1016/j.jclinepi.2018.09.003

Salanti, Georgia, Nikolakopoulou, Adriani, Sutton, Alex J., Reichenbach, Stephan, Trelle, Sven, Naci, Huseyin, Egger, Matthias (2018). Planning a future randomized clinical trial based on a network of relevant past trials. Trials, 19(365). https://doi.org/10.1186/s13063-018-2740-2

Wallach, Joshua D., Ross, Joseph S., Naci, Huseyin (2018). The US Food and Drug Administration’s expedited approval programs: addressing premarket flexibility with enhanced postmarket evidence generation. Clinical Trials, 15(3), 243-246. https://doi.org/10.1177/1740774518770657

Naci, Huseyin (2017). What to do (or not to do) when randomization is not possible. Journal of Heart and Lung Transplantation, 36(11), 1174-1177. https://doi.org/10.1016/j.healun.2017.07.008

Wenzl, Martin, Naci, Huseyin, Mossialos, Elias (2017). Health policy in times of austerity — a conceptual framework for evaluating effects of policy on efficiency and equity illustrated with examples from Europe since 2008. Health Policy, 121(9), 947-954. https://doi.org/10.1016/j.healthpol.2017.07.005

Naci, Huseyin, Smalley, Katelyn R., Kesselheim, Aaron S. (2017). Characteristics of preapproval and postapproval studies for drugs granted accelerated approval by the US food and drug administration. JAMA, 318(7), 626-636. https://doi.org/10.1001/jama.2017.9415

Naci, Huseyin, Wouters, Olivier J., Gupta, Radhika, Ioannidis, John P. A. (2017). Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval. The Milbank Quarterly, 95(2), 261 - 290. https://doi.org/10.1111/1468-0009.12261

Kaier, K., Reinecke, H., Naci, Huseyin, Frankenstein, L., Bode, M., Vach, W., Hehn, P., Zirlik, A., Zehender, M., Reinöhl, J. (2017). The impact of post-procedural complications on reimbursement, length of stay and mechanical ventilation among patients undergoing transcatheter aortic valve implantation in Germany. European Journal of Health Economics, 19(2), 223-228. https://doi.org/10.1007/s10198-017-0877-7

Naci, Huseyin, Soumerai, Stephen B. (2016). History bias, study design, and the unfulfilled promise of pay-for-performance policies in health care. Preventing Chronic Disease, 13(160133), 1-7. https://doi.org/10.5888/pcd13.160133

Wouters, Olivier J., Naci, Huseyin, Samani, Nilesh J (2015). QALYs in cost-effectiveness analysis: an overview for cardiologists. Heart, 10(23), 1868-1873. https://doi.org/10.1136/heartjnl-2015-308255

Naci, Huseyin, Basu, Sanjay, Yudkin, John S (2015). Preventing cardiovascular events with empagliflozin: at what cost? The Lancet Diabetes and Endocrinology, 3(12), p. 931. https://doi.org/10.1016/S2213-8587(15)00439-8

Naci, Huseyin, Carter, Alexander W., Mossialos, Elias (2015). Why the drug development pipeline is not delivering better medicines. BMJ, 351, https://doi.org/10.1136/bmj.h5542

Tervonen, Tommi, Naci, Huseyin, van Valkenhoef, Gert, Ades, Anthony E., Angelis, Aris, Hillege, Hans L., Postmus, Douwe (2015). Applying multiple criteria decision analysis to comparative benefit-risk assessment: choosing among statins in primary prevention. Medical Decision Making, 35(7), 859-871. https://doi.org/10.1177/0272989X15587005

Naci, Huseyin, Carter, Alexander W., Mossialos, Elias (2015). Double failure: the shared accountability of governments and firms for the innovation deficit in the pharmaceutical sector. BMJ,

Naci, Huseyin, Ioannidis, John P. A. (2015). Evaluation of wellness determinants and interventions by citizen scientists. JAMA, 314(2), p. 121.

Mossialos, Elias, Courtin, Emilie, Naci, Huseyin, Benrimoj, Shalom, Bouvy, Marcel, Farris, Karen, Noyce, Peter, Sketris, Ingrid (2015). From "retailers" to health care providers: transforming the role of community pharmacists in chronic disease management. Health Policy, 119(5), 628-639. https://doi.org/10.1016/j.healthpol.2015.02.007

Naci, Huseyin, Ioannidis, John P. A. (2015). How good is "Evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of clinical utility of drugs. Annual Review of Pharmacology and Toxicology, 55, 169-189. https://doi.org/10.1146/annurev-pharmtox-010814-124614

Jackson, N., Atar, D., Borentain, M., Breithardt, G., van Eickels, M., Endres, M., Fraass, U., Friede, T., Hannachi, H. & Janmohamed, S. et al (2015). Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. European Heart Journal, https://doi.org/10.1093/eurheartj/ehv213

Naci, Huseyin, Spackman, Eldon, Fleurence, Rachael (2015). National approaches to comparative effectiveness research. In Sobolev, Boris (Ed.), Handbook of Health Services Research . Springer Berlin / Heidelberg.

Naci, Huseyin, Lehman, Richard, Wouters, Olivier J., Goldacre, Ben, Yudkin, John S (2015). Rethinking the appraisal and approval of drugs for type 2 diabetes. BMJ, 351(h5260). https://doi.org/10.1136/bmj.h5260

Naci, Huseyin, Cooper, Jacob, Mossialos, Elias (2015). Timely publication and sharing of trial data: opportunities and challenges for comparative effectiveness research in cardiovascular disease. European Heart Journal - Quality of Care and Clinical Outcomes, https://doi.org/10.1093/ehjqcco/qcv012

Chambers, James D., Naci, Huseyin, Wouters, Olivier J., Pyo, Junhee, Gunjal, Shalak, Kennedy, Ian R., Hoey, Mark G., Winn, Aaron, Neumann, Peter J. (2015). An assessment of the methodological quality of published network meta-analyses: a systematic review. PLOS ONE, 10(4). https://doi.org/10.1371/journal.pone.0121715

Naci, Huseyin (2014). Does industry sponsorship bias research findings?

Naci, Huseyin, Dias, Sofia, Ades, A. E. (2014). Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ, 349(oct03), g5741-g5741. https://doi.org/10.1136/bmj.g5741

Naci, Huseyin, Alexander, George Caleb (2014). Regulators should better leverage effectiveness standards to enhance drug value. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 34(10), 1005-1011. https://doi.org/10.1002/phar.1467

Naci, Huseyin, van Valkenhoef, G., Higgins, J. P. T., Fleurence, R., Ades, A. E. (2014). Evidence-based prescribing: combining network meta-analysis with multicriteria decision analysis to choose among multiple drugs. Circulation: Cardiovascular Quality and Outcomes, 7(5), 787-792. https://doi.org/10.1161/CIRCOUTCOMES.114.000825

Naci, Huseyin, Soumerai, Stephen B, Ross-Degnan, Dennis, Zhang, Fang, Briesacher, Becky A., Gurwitz, Jerry H., Madden, Jeanne M. (2014). Medication affordability gains following Medicare Part D are eroding among elderly with multiple chronic conditions. Health Affairs, 33(8), 1435-1443. https://doi.org/10.1377/hlthaff.2013.1067

Naci, Huseyin (2014). Persistent medication affordability problems among disabled medicare beneficiaries after Part D, 2006-2011. Medical Care, 52(11), 951-956. https://doi.org/10.1097/MLR.0000000000000205

Naci, H., Brugts, J. J., Fleurence, R., Tsoi, B., Toor, H., Ades, A. E. (2013). Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: A network meta-analysis of placebo-controlled and active-comparator trials. European Journal of Preventive Cardiology, 20(4), 641-657. https://doi.org/10.1177/2047487313480435

Naci, Huseyin, Brugts, Jasper Jan, Fleurence, Rachael, Ades, Anthony E. (2013). Dose-comparative effects of different statins on serum lipid levels: a network meta-analysis of 256,827 individuals in 181 randomized controlled trials. European Journal of Preventive Cardiology, 20(4), 658-670. https://doi.org/10.1177/2047487313483600

Naci, Huseyin, Brugts, Jasper Jan, Ades, Tony (2013). Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circulation: Cardiovascular Quality and Outcomes, 6(4), 390-399. https://doi.org/10.1161/CIRCOUTCOMES.111.000071

Jansen, Jeroen P., Naci, Huseyin (2013). Is network meta-analysis as valid as standard pairwise meta-analysis? It all depends on the distribution of effect modifiers. BMC Medicine, 11(1), p. 159. https://doi.org/10.1186/1741-7015-11-159

Winter, H.S., Mossialos, E., Naci, Huseyin, Chandra, A., Salojee, H., Yamashiro, Y., Bhutta, Z.A., Uauy, R., Corvalan, C. (2012). The economics of health care delivery. Journal of Pediatric Gastroenterology and Nutrition, 55(5), 482-488. https://doi.org/10.1097/MPG.0b013e318272af3b

Naci, Huseyin, Cylus, Jonathan, Vandoros, Sotiris, Sato, Azusa, Perampaladas, Kumar (2012). Raising the bar for market authorisation of new drugs. The BMJ, 345, e4261-e4261. https://doi.org/10.1136/bmj.e4261

Chisholm, Daniel, Naci, Huseyin, Hyder, Adnan Ali, Tran, Nhan T., Peden, Margie (2012). Cost effectiveness of strategies to combat road traffic injuries in sub-Saharan Africa and South East Asia: mathematical modelling study. BMJ, 344(mar02), e612-e612. https://doi.org/10.1136/bmj.e612

Naci, Huseyin, Fleurence, Rachael (2011). Using indirect evidence to determine the comparative effectiveness of prescription drugs: do benefits outweigh risks? Health Outcomes Research in Medicine, 2(4), e241-e249.

Sorenson, Corinna, Naci, Huseyin, Cylus, Jonathan, Mossialos, Elias (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal, 343(7822), d4849-d4849. https://doi.org/10.1136/bmj.d4849

Naci, Huseyin (2011). The increasing need to harmonize evidence demands of regulators, payers, and health technology assessment bodies in Europe – opportunities and challenges. ISPOR Connections, 17(4), 4-6.

Fleurence, Rachel L., Naci, Huseyin, Jansen, Jeroen P. (2010). The critical role of observational evidence in comparative effectiveness research. Health Affairs, 29(10), 1826-1833. https://doi.org/10.1377/hlthaff.2010.0630

McIntyre, Roger S., Cragin, Lael, Sorensen, Sonja, Naci, Huseyin, Baker, Tim, Roussy, Jean-Pascal (2010). Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis. Journal of Evaluation in Clinical Practice, 16(4), 744-755. https://doi.org/10.1111/j.1365-2753.2009.01189.x

Naci, Huseyin, Fleurence, Rachael, Birt, Julie, Duhig, Amy (2010). Economic burden of multiple sclerosis. PharmacoEconomics, 28(5), 363-379. https://doi.org/10.2165/11532230-000000000-00000

Naci, Huseyin, Fleurence, Rachael, Birt, Julie, Duhig, Amy (2010). The impact of increasing neurological disability of multiple sclerosis on health utilities: a systematic review of the literature. Journal of Medical Economics, 13(1), 78-89. https://doi.org/10.3111/13696990903543085

Naci, H., Chisholm, D., Baker, T. D. (2009). Distribution of road traffic deaths by road user group: a global comparison. Injury Prevention, 15(1), 55-59. https://doi.org/10.1136/ip.2008.018721

Chisholm, Dan, Naci, Huseyin (2008). Road traffic injury prevention: an assessment of risk exposure and intervention cost-effectiveness in different world regions. (HSF discussion papers). World Health Organization.

Naci, Huseyin, Baker, Timothy D. (2008). Productivity losses from road traffic deaths in Turkey. International Journal of Injury Control and Safety Promotion, 15(1), 19-24. https://doi.org/10.1080/17457300701847648

Naci, Huseyin, Leontsini, Elli, Baker, Timothy D. (2007). One island, two parts, shared aspirations. Harvard Health Policy Review, Fall(2), 108-110.

Lifecourse, Ageing & Population Health

Mossialos, Elias, Courtin, Emilie, Naci, Huseyin, Benrimoj, Shalom, Bouvy, Marcel, Farris, Karen, Noyce, Peter, Sketris, Ingrid (2015). From "retailers" to health care providers: transforming the role of community pharmacists in chronic disease management. Health Policy, 119(5), 628-639. https://doi.org/10.1016/j.healthpol.2015.02.007

Mossialos, Elias, Naci, Huseyin, Courtin, Emilie (2013). Expanding the role of community pharmacists: policymaking in the absence of policy-relevant evidence? Health Policy, 111(2), 135-148. https://doi.org/10.1016/j.healthpol.2013.04.003

Rahmioglu, Nilufer, Naci, Huseyin, Cylus, Jonathan (2012). Improving health care services in Northern Cyprus: a call for research and action. European Journal of Public Health, 22(6), 754-755. https://doi.org/10.1093/eurpub/cks145

Naci, Huseyin, Cylus, Jonathan (2012). Why a stricter regulation of drugs could foster (not deter) pharmaceutical innovation.

Naci, Huseyin, Cylus, Jonathan, Vandoros, Sotiris, Sato, Azusa, Perampaladas, Kumar (2012). Raising the bar for market authorisation of new drugs. The BMJ, 345, e4261-e4261. https://doi.org/10.1136/bmj.e4261

Sorenson, Corinna, Naci, Huseyin, Cylus, Jonathan, Mossialos, Elias (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal, 343(7822), d4849-d4849. https://doi.org/10.1136/bmj.d4849

Methodology

Naci, Huseyin, Salcher-Konrad, Maximilian, Mcguire, Alistair, Berger, Felix, Kuehne, Titus, Goubergrits, Leonid, Muthurangu, Vivek, Wilson, Ben, Kelm, Marcus (2019). Impact of predictive medicine on therapeutic decision making: a randomized controlled trial in congenital heart disease. npj Digital Medicine, 2(1). https://doi.org/10.1038/s41746-019-0085-1

Psychological and Behavioural Science

Pollicino, Daniele, Zamzow, Heidi, Shreedhar, Ganga, Galizzi, Matteo M., Naci, Huseyin, Freitag, Patricia (2025). Can social norms promote sustainable food consumption? A systematic review. Social Influence, 20(1). https://doi.org/10.1080/15534510.2025.2497341

Social Policy

Naci, Huseyin (2016). Communication of treatment rankings obtained from network meta-analysis using data visualization. Circulation: Cardiovascular Quality and Outcomes, 9(5), 605-608. https://doi.org/10.1161/CIRCOUTCOMES.116.002874

Dhutia, Harshil, Malhotra, Aneil, Gabus, Vincent, Merghani, Ahmed, Finocchiaro, Gherardo, Millar, Lynne, Narain, Rajay, Papadakis, Michael, Naci, Huseyin & Tome, Maite et al (2016). Cost implications of using different ECG criteria for screening young athletes in the United Kingdom. Journal of the American College of Cardiology, 68(7), 702-711. https://doi.org/10.1016/j.jacc.2016.05.076

Naci, Huseyin, Soumerai, Stephen B. (2016). History bias, study design, and the unfulfilled promise of pay-for-performance policies in health care. Preventing Chronic Disease, 13(160133), 1-7. https://doi.org/10.5888/pcd13.160133

Luyten, Jeroen, Naci, Huseyin, Knapp, Martin (2016). Economic evaluation of mental health interventions: an introduction to cost-utility analysis. Evidence-Based Mental Health, 19, 49-53. https://doi.org/10.1136/eb-2016-102354

Tervonen, Tommi, Naci, Huseyin, van Valkenhoef, Gert, Ades, Anthony E., Angelis, Aris, Hillege, Hans L., Postmus, Douwe (2015). Applying multiple criteria decision analysis to comparative benefit-risk assessment: choosing among statins in primary prevention. Medical Decision Making, 35(7), 859-871. https://doi.org/10.1177/0272989X15587005

Naci, Huseyin, Carter, Alexander W., Mossialos, Elias (2015). Double failure: the shared accountability of governments and firms for the innovation deficit in the pharmaceutical sector. BMJ,

Mossialos, Elias, Courtin, Emilie, Naci, Huseyin, Benrimoj, Shalom, Bouvy, Marcel, Farris, Karen, Noyce, Peter, Sketris, Ingrid (2015). From "retailers" to health care providers: transforming the role of community pharmacists in chronic disease management. Health Policy, 119(5), 628-639. https://doi.org/10.1016/j.healthpol.2015.02.007

Naci, Huseyin, Cooper, Jacob, Mossialos, Elias (2015). Timely publication and sharing of trial data: opportunities and challenges for comparative effectiveness research in cardiovascular disease. European Heart Journal - Quality of Care and Clinical Outcomes, https://doi.org/10.1093/ehjqcco/qcv012

Naci, Huseyin (2014). Generating comparative data on clinical benefits and harms of statins to inform prescribing decisions: evidence from network meta-analyses [Doctoral thesis]. London School of Economics and Political Science.

Naci, Huseyin, O’Connor, Alec B (2013). Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses. Journal of Clinical Epidemiology, 66(8), 812-816. https://doi.org/10.1016/j.jclinepi.2013.04.002

Mossialos, Elias, Naci, Huseyin, Courtin, Emilie (2013). Expanding the role of community pharmacists: policymaking in the absence of policy-relevant evidence? Health Policy, 111(2), 135-148. https://doi.org/10.1016/j.healthpol.2013.04.003

Winter, H.S., Mossialos, E., Naci, Huseyin, Chandra, A., Salojee, H., Yamashiro, Y., Bhutta, Z.A., Uauy, R., Corvalan, C. (2012). The economics of health care delivery. Journal of Pediatric Gastroenterology and Nutrition, 55(5), 482-488. https://doi.org/10.1097/MPG.0b013e318272af3b

Naci, Huseyin, de Lissovoy, Gregory, Hollenbeak, Christopher, Custer, Brian, Hofmann, Axel, McClellan, William, Gitlin, Matthew (2012). Historical clinical and economic consequences of anemia management in patients with end-stage renal disease on dialysis using erythropoietin stimulating agents versus routine blood transfusions: a retrospective cost-effectiveness analysis. Journal of Medical Economics, 15(2), 293-304. https://doi.org/10.3111/13696998.2011.644407

Naci, Huseyin, Fleurence, Rachael (2011). Using indirect evidence to determine the comparative effectiveness of prescription drugs: do benefits outweigh risks? Health Outcomes Research in Medicine, 2(4), e241-e249.

Sorenson, Corinna, Naci, Huseyin, Cylus, Jonathan, Mossialos, Elias (2011). Evidence of comparative efficacy should have a formal role in European drug approvals. British Medical Journal, 343(7822), d4849-d4849. https://doi.org/10.1136/bmj.d4849